Inhibikase Therapeutics (IKT) EBITDA Margin (2021 - 2026)
Inhibikase Therapeutics (IKT) reported EBITDA Margin of -439699800.00% for Q4 2023, down 439692988.29 percentage points from -6811.71% a year earlier and down 439693814.87 percentage points from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) EBITDA Margin (2021 - 2026) Analysis & Trends
For FY2023, Inhibikase Therapeutics posted EBITDA Margin of -7643.88%, up 7036.84 percentage points from FY2022.
- By year, EBITDA Margin came in at -14680.72% in FY2022 (-14204.49 pp) and -476.23% in FY2021.
- The Q4 2023 figure ranks as the lowest quarterly EBITDA Margin in data going back to Q4 2021.
- Year over year, EBITDA Margin gained in four of the last five quarters, with an average year-over-year change of -87863233.34 percentage points.
- Per Business Quant data, the three quarters before Q4 2023 came in at -5985.13% (Q3 2023), -5191.30% (Q2 2023) and -7299.80% (Q1 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Inhibikase Therapeutics | 281.11 Mn | -420.36 Mn | - | -1,261.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -1,261.78% |
| Jun 30, 2026 | -1,442.08% |
| Mar 31, 2026 | -1,221.15% |
| Dec 31, 2025 | -1,324.49% |
| Sep 30, 2025 | -1,519.04% |
| Jun 30, 2025 | -1,178.95% |
| Mar 31, 2025 | -1,586.62% |
| Dec 31, 2023 | -439,699,800.00% |
| Sep 30, 2023 | -5,985.13% |
| Jun 30, 2023 | -5,191.30% |
| Mar 31, 2023 | -7,299.80% |
| Dec 31, 2022 | -6,811.71% |
| Sep 30, 2022 | -61,876.53% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,081.46% |
| Dec 31, 2021 | -259,334.41% |
API Access
Inhibikase Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();